Brind.

Abbott Laboratories Plans Business Separation Amid Rating Upgrades

2 reports, 2 independent Updated Oct 21
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Abbott Laboratories reported $1.42 EPS and $13.01 billion in revenue for the quarter, exceeding analyst estimates. Citigroup raised its price objective for Abbott Laboratories to $112.00 and issued a "buy" rating. Separately, Abbott Laboratories announced plans to separate its nutrition business into a publicly traded company, a move similar to Johnson & Johnson.

From dailypolitical.com, rte.ie

Why it matters

Some supportBrind's analysis of the reports

Abbott Laboratories cut its 2026 sales growth forecast and now expects growth of about 6%. The company is reshaping its portfolio to offload underperforming businesses, including the nutrition division. These strategic changes, combined with analyst rating updates, influence investor confidence and valuation.

From dailypolitical.com, rte.ie

Who's involved

  • CitigroupCitigroup issued a "buy" rating and raised the price objective for Abbott Laboratories.
  • Abbott LaboratoriesAbbott Laboratories reported quarterly earnings and announced plans to separate its nutrition business.
  • Royal Bank of CanadaRoyal Bank of Canada reissued an "outperform" rating for Abbott Laboratories.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Abbott LaboratoriesSpeculative

    Abbott Laboratories' market price could be affected by rating upgrades from Citigroup and Royal Bank of Canada, boosting investor confidence and valuation.

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

How it developed

Newest first. Tap a step to see who reported it.
  1. Citigroup and RBC issued rating and price objective updates for Abbott Laboratories.1 source
  2. Abbott and J&J plan separation; Abbott plant shuts down; RBC views forecast unfavourably.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped